Significant clinical response of advanced colon cancer to peptide vaccine therapy: A case report

Tokai Journal of Experimental and Clinical Medicine

Volumn 37, Issue 2, 2012, Pages 57-61

  Yasuda, Seiei ^a   Tsuchiya, Izumi ^a   Okada, Kazutake ^a   Tanaka, Akira ^a   Suzuki, Toshiyuki ^a   Sadahiro, Sotaro ^a   Takeda, Kazuyoshi ^b   Yamamoto, Soichiro ^a   Nakui, Minoru ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Immunotherapy; Partial response; Peptide vaccine; Vaccine

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; NARCOTIC ANALGESIC AGENT; OXALIPLATIN; PEPTIDE VACCINE; UFT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDRONEPHROSIS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PELVIS LYMPH NODE; PELVIS PAIN SYNDROME; PROTEIN BLOOD LEVEL; RECTUM ANTERIOR RESECTION; SIGMOIDECTOMY; URETER STENT; URINARY CATHETER;

ADENOCARCINOMA; CANCER VACCINES; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; ONCOGENE PROTEINS; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOMOGRAPHY, X-RAY COMPUTED; VACCINES, SUBUNIT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84864433531     PISSN: 03850005     EISSN: 21852243     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Merika E, Saif MW, Katz A, Syrigos C, Morse M. Colon cancer vaccine: an update. In Vivo 2010; 24: 607-628.
2. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res 2004; 10: 8577-8586.
3. Okuno K, Sugiura F, Hida J, Tokoro T, Ishimaru E, Sukegawa Y, et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med 2011; 2: 73-79.
4. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y, Furukawa Y. Identi_cation of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol 2006; 29: 381-386.
5. Li D, Yan D, Tang H, Zhou C, Fan J, Li S, et al. IPM3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009; 16: 3499-3506.
6. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2006; 12: 5841-5849.
7. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005; 65: 4939-4946.
8. Miyazawa M, Ohsawa R, Tsunoda T, Hirano S, Kawai M, Tani M, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101: 433-439.
9. Nagorsen D, Thiel E. Clinical and immunologic response to active speci_c cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12: 3064-3069.
10. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809-8814.
11. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nature Rev Drug Discov 2011; 10: 591-600.
12. Madan RA, Gulley JL, Fojo T, Dahut W. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. The Oncologist 2010; 15: 969-975.